If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

Pandion Therapeutics, Inc. (PAND)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases. They have combined a network-based conceptualization of the immune system with expertise in advanced protein engineering to develop their TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform. Their TALON platform enables them to employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. They are also able to combine an effector module with a tissue-targeted tether module in a bifunctional format to guide delivery of the effector to a targeted tissue. Their lead product candidate, PT101, a combination of their interleukin-2, or IL-2, mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells, or Treg cells, systemically, without activating proinflammatory cells, such as conventional T cells and natural killer, or NK, cells. They are initially developing PT101 for the treatment of patients with moderate-to-severe ulcerative colitis, or UC, and are currently conducting a Phase 1a clinical trial of PT101 in healthy volunteers, with final data expected in the first half of 2021. Leveraging their TALON platform, they continue to develop and expand their library of effector and tether modules as part of their early stage research and discovery pipeline.
Rahul Kakkar Gregg Beloff
Employees Founded
43 2017


Address: 134 Coolidge Avenue, Watertown, MA 02472, US

Telephone: (617) 393-5925

Web page:

IPO information

Expected Date 7/17/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $475.9
Revenues (MM) $2.97
Net Income (Loss) (MM) $-27.0


What do you think will happen with the PAND share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 5.5
Shares Revised (MM) 7.5
Expected offer amount (MM) $93.5
Realized offer amount(MM) $135
Goldman Sachs/ Morgan Stanley/ SVB Leerink/ BMO Capital Markets

Sector: Healthcare

Tweets about $PAND

Tweets volume:

RT volume:


Google Trends Stats